MedTrace Logo

Study Evaluating the Safety and Efficacy of Proellex® in the Treatment of Endometriosis-extension Study

NCT00958412 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2019-02-12

Study results available
· View outcomes & findings →

Summary

ZPE-201 Extension of treatment

Conditions

  • Endometriosis

Interventions

DRUG

Proellex®

one (1) 25 mg capsule daily

Sponsors & Collaborators

  • Repros Therapeutics Inc.

    lead INDUSTRY

Principal Investigators

  • Anna Chan · Allergan

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
48 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2009-08-31
Completion
2009-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00958412 on ClinicalTrials.gov